PMID- 35656076 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20220716 IS - 2008-3866 (Print) IS - 2008-3874 (Electronic) IS - 2008-3866 (Linking) VI - 25 IP - 4 DP - 2022 Apr TI - Epigallocatechin-3-gallate alleviates type 2 diabetes mellitus via beta-cell function improvement and insulin resistance reduction. PG - 483-488 LID - 10.22038/IJBMS.2022.58591.13016 [doi] AB - OBJECTIVES: Epigallocatechin-3-gallate (EGCG) has a good therapeutic effect on type 2 diabetes mellitus (T2DM). This work was designed to explore EGCG's effectiveness in insulin resistance (IR) and pancreas islet beta-cell function in a rat model of T2DM. MATERIALS AND METHODS: Eight-week-old male Sprague Dawley rats were randomly divided into 6 groups, including the Control (normal diet), Diabetes (high-sucrose high-fat [HSHF] diet combined with tail vein injection of streptozotocin [STZ] for T2DM induction) and Treatment Diabetic rats which were treated with metformin [500 mg/kg/d] or EGCG [25, 50 or 100 mg/kg/d] intragastric administration for 10 weeks. With the exception of control animals, the other groups were fed the HSHF diet. EGCG's effects on IR and insulin secretion were assessed by measuring body weights, and fasting blood glucose (FBG), postprandial blood glucose (PBG) and insulin levels. The morphological and molecular changes of pancreas islet beta-cells were examined by hematoxylin-eosin (H&E) staining, transmission electron microscopy (TEM) and immunofluorescence. RESULTS: Rats fed the HSHF diet combined with STZ treatment had increased body weights and blood glucose amounts, accompanied by IR and impaired beta-cell function, induced T2DM, and EGCG dose-dependently restored the above indicators. Additionally, EGCG upregulated the pancreatic transcription factors pancreatic duodenal homeobox protein-1 (PDX-1) and musculoaponeurotic fibrosarcoma oncogene homolog A (MafA). CONCLUSION: These results suggest that EGCG reduces blood glucose amounts, and improve IR and islet beta-cell disorder in T2DM. FAU - Zhu, Tiantian AU - Zhu T AD - College of Pharmacy, Xinxiang Medical University, Xinxiang, China. AD - Henan International Joint Laboratory of Cardiovascular Remodeling and Drug Intervention, Xinxiang, China. AD - Xinxiang Key Laboratory of Vascular Remodeling Intervention and Molecular Targeted Therapy Drug Development, Xinxiang, China. AD - These authors contributed equally to this work. FAU - Li, Minghui AU - Li M AD - College of Pharmacy, Xinxiang Medical University, Xinxiang, China. AD - Henan International Joint Laboratory of Cardiovascular Remodeling and Drug Intervention, Xinxiang, China. AD - Xinxiang Key Laboratory of Vascular Remodeling Intervention and Molecular Targeted Therapy Drug Development, Xinxiang, China. AD - These authors contributed equally to this work. FAU - Zhu, Moli AU - Zhu M AD - College of Pharmacy, Xinxiang Medical University, Xinxiang, China. AD - Henan International Joint Laboratory of Cardiovascular Remodeling and Drug Intervention, Xinxiang, China. AD - Xinxiang Key Laboratory of Vascular Remodeling Intervention and Molecular Targeted Therapy Drug Development, Xinxiang, China. FAU - Liu, Xu AU - Liu X AD - College of Pharmacy, Xinxiang Medical University, Xinxiang, China. AD - Henan International Joint Laboratory of Cardiovascular Remodeling and Drug Intervention, Xinxiang, China. AD - Xinxiang Key Laboratory of Vascular Remodeling Intervention and Molecular Targeted Therapy Drug Development, Xinxiang, China. FAU - Huang, Keke AU - Huang K AD - College of Pharmacy, Xinxiang Medical University, Xinxiang, China. AD - Henan International Joint Laboratory of Cardiovascular Remodeling and Drug Intervention, Xinxiang, China. AD - Xinxiang Key Laboratory of Vascular Remodeling Intervention and Molecular Targeted Therapy Drug Development, Xinxiang, China. FAU - Li, Wenru AU - Li W AD - College of Pharmacy, Xinxiang Medical University, Xinxiang, China. AD - Henan International Joint Laboratory of Cardiovascular Remodeling and Drug Intervention, Xinxiang, China. AD - Xinxiang Key Laboratory of Vascular Remodeling Intervention and Molecular Targeted Therapy Drug Development, Xinxiang, China. FAU - Wang, Shuang-Xi AU - Wang SX AD - College of Pharmacy, Xinxiang Medical University, Xinxiang, China. AD - Henan International Joint Laboratory of Cardiovascular Remodeling and Drug Intervention, Xinxiang, China. AD - Xinxiang Key Laboratory of Vascular Remodeling Intervention and Molecular Targeted Therapy Drug Development, Xinxiang, China. AD - These authors contributed equally to this work. FAU - Yin, Yaling AU - Yin Y AD - Henan International Joint Laboratory of Cardiovascular Remodeling and Drug Intervention, Xinxiang, China. AD - Xinxiang Key Laboratory of Vascular Remodeling Intervention and Molecular Targeted Therapy Drug Development, Xinxiang, China. AD - School of Basic Medical Sciences, Xinxiang Medical University, Xinxiang, China. FAU - Li, Peng AU - Li P AD - College of Pharmacy, Xinxiang Medical University, Xinxiang, China. AD - Henan International Joint Laboratory of Cardiovascular Remodeling and Drug Intervention, Xinxiang, China. AD - Xinxiang Key Laboratory of Vascular Remodeling Intervention and Molecular Targeted Therapy Drug Development, Xinxiang, China. LA - eng PT - Journal Article PL - Iran TA - Iran J Basic Med Sci JT - Iranian journal of basic medical sciences JID - 101517966 PMC - PMC9150804 OTO - NOTNLM OT - Epigallocatechin-3-gallate OT - Insulin resistance OT - Insulin secretion OT - Pancreatic duodenal - homeobox protein-1 OT - Type 2 diabetes mellitus OT - beta-cell COIS- The authors have no conflict of interest. EDAT- 2022/06/04 06:00 MHDA- 2022/06/04 06:01 PMCR- 2022/04/01 CRDT- 2022/06/03 02:23 PHST- 2021/06/26 00:00 [received] PHST- 2022/04/18 00:00 [accepted] PHST- 2022/06/03 02:23 [entrez] PHST- 2022/06/04 06:00 [pubmed] PHST- 2022/06/04 06:01 [medline] PHST- 2022/04/01 00:00 [pmc-release] AID - 10.22038/IJBMS.2022.58591.13016 [doi] PST - ppublish SO - Iran J Basic Med Sci. 2022 Apr;25(4):483-488. doi: 10.22038/IJBMS.2022.58591.13016.